An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

 

 Permissions and Reprints

Abstract

This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

Publication History

Received: 10 June 2021
Received: 23 August 2021

Accepted: 23 August 2021

Article published online:
15 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 de Leon J, Ruan CJ, Schoretsanitis G. et al. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom 2020; 89: 200-204
  CrossrefPubMedGoogle Scholar
• 2 Kane J, Honigfeld G, Singer J. et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
  CrossrefPubMedGoogle Scholar
• 3 de Leon J, Ruan CJ, Schoretsanitis G. et al. Dose and safety concerns of clozapine: worldwide package inserts need revisions. Schizophr Res 2020; 216: 2-4
  CrossrefPubMedGoogle Scholar
• 4 Nielsen J, Young C, Ifteni P. et al. Worldwide differences in regulations of clozapine use. CNS Drugs 2016; 30: 149-161
  CrossrefPubMedGoogle Scholar
• 5 Howes OD, McCutcheon R, Agid O. et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216-229
  CrossrefPubMedGoogle Scholar
• 6 Siskind D, McCartney L, Goldschlager R. et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385-392
  CrossrefPubMedGoogle Scholar
• 7 Samara MT, Dold M, Gianatsi M. et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry 2016; 73: 199-210
  CrossrefPubMedGoogle Scholar
• 8 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939-951
  CrossrefPubMedGoogle Scholar
• 9 Land R, Siskind D, McArdle P. et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 2017; 135: 296-309
  CrossrefPubMedGoogle Scholar
• 10 Masuda T, Misawa F, Takase M. et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: A systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019; 76: 1052-1062
  CrossrefPubMedGoogle Scholar
• 11 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301
  CrossrefPubMedGoogle Scholar
• 12 Vermeulen JM, van Rooijen G, van de Kerkhof MPJ. et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull 2019; 45: 315-329
  CrossrefPubMedGoogle Scholar
• 13 Cho J, Hayes RD, Jewell A. et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 2019; 139: 237-247
  CrossrefPubMedGoogle Scholar
• 14 van der Zalm Y, Foldager L, Termorshuizen F. et al. Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 2021; 143: 216-226
  CrossrefPubMedGoogle Scholar
• 15 Taipale H, Tanskanen A, Mehtälä J. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61-68
  CrossrefPubMedGoogle Scholar
• 16 Tiihonen J, Lönnqvist J, Wahlbeck K. et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627
  CrossrefPubMedGoogle Scholar
• 17 Bachmann CJ, Aagaard L, Bernardo M. et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 2017; 136: 37-51
  CrossrefPubMedGoogle Scholar
• 18 Meltzer HY, Alphs L, Green AI. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
  CrossrefPubMedGoogle Scholar
• 19 Citrome L, Volavka J. Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine. Harv Rev Psychiatry 2021; 29: 20-34
  CrossrefPubMedGoogle Scholar
• 20 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9-62
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Schoretsanitis G, Kane JM, Correll CU. et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 2020; 81: 19cs13169
  CrossrefPubMedGoogle Scholar
• 22 Williams RL. FDA position on product selection for “narrow therapeutic index” drugs. Am J Health Syst Pharm 1997; 54: 1630-1632
  CrossrefPubMedGoogle Scholar
• 23 Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2016; 12: 407-422
  CrossrefPubMedGoogle Scholar
• 24 Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007; 167: 1752-1759
  CrossrefPubMedGoogle Scholar
• 25 de Leon J, Sanz EJ, De Las Cuevas C. Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 2020; 46: 1-3
  CrossrefPubMedGoogle Scholar
• 26 de Leon J, Sanz EJ, Norén GN. et al. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry 2020; 19: 120-121
  CrossrefPubMedGoogle Scholar
• 27 Rohde C, Siskind D, de Leon J. et al. Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study. Acta Psychiatr Scand 2020; 142: 78-86
  CrossrefPubMedGoogle Scholar
• 28 Villasante-Tezanos AG, Rohde C, Nielsen J. et al. Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiat Scand 2020; 142: 66-67
  CrossrefPubMedGoogle Scholar
• 29 Schoretsanitis G, Ruan CJ, Rohde C. et al. An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol 2021; 24: 1-5
  PubMedGoogle Scholar
• 30 Vohra J. Sudden cardiac death in schizophrenia: a review. Heart Lung Circ 2020; 29: 1427-1432
  CrossrefPubMedGoogle Scholar
• 31 Papola D, Ostuzzi G, Gastaldon C. et al. Antipsychotic use and risk of life- threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand 2019; 140: 227-243
  CrossrefPubMedGoogle Scholar
• 32 Myles N, Myles H, Xia S. et al. A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry 2019; 53: 403-412
  CrossrefPubMedGoogle Scholar
• 33 Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol 2018; 25: 22-28
  CrossrefPubMedGoogle Scholar
• 34 Winckel K, Siskind D, Hollingworth S. et al. Clozapine-induced myocarditis: separating the wheat from the chaff. Aust N Z J Psychiatry 2015; 49: 188
  CrossrefPubMedGoogle Scholar
• 35 Ronaldson KJ, Fitzgerald PB, Taylor AJ. et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust NZ J Psychiatry 2011; 45: 458-465
  CrossrefPubMedGoogle Scholar
• 36 Ronaldson KJ, Fitzgerald PB, Taylor AJ. et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012; 141: 173-178
  CrossrefPubMedGoogle Scholar
• 37 Shirazi A, Stubbs B, Gomez L. et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci 2016; 17: 863
  CrossrefPubMedGoogle Scholar
• 38 West S, Rowbotham D, Xiong G. et al. Clozapine induced gastrointestinal hypomotility: a potentially life threatening adverse event. A review of the literature. Gen Hosp Psychiatry 2017; 46: 32-37
  CrossrefPubMedGoogle Scholar
• 39 Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs 2017; 31: 1083-1091
  CrossrefPubMedGoogle Scholar
• 40 de Leon J, Schoretsanitis G, Kane JM. et al. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia Pac Psychiatry 2020; 12: e12384
  CrossrefPubMedGoogle Scholar
• 41 Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2014; 10: 721-746
  CrossrefPubMedGoogle Scholar
• 42 Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247-2249
  CrossrefPubMedGoogle Scholar
• 43 Clancy MJ, Clarke MC, Connor DJ. et al. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 75
  CrossrefPubMedGoogle Scholar
• 44 Asenjo Lobos C, Komossa K, Rummel-Kluge C. et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; CD006633
  PubMedGoogle Scholar
• 45 Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab 2011; 12: 611-620
  CrossrefPubMedGoogle Scholar
• 46 Nielsen J, Correll CU, Manu P. et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. J Clin Psychiatry 2013; 74: 603-613
  CrossrefPubMedGoogle Scholar
• 47 Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil 2006; 27: 309-336
  CrossrefPubMedGoogle Scholar
• 48 Sandoz, Inc. CLOZAPINE tablet [Package insert]. Sandoz Inc. Princeton, NJ. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e503b3cd-574e-ed6a-c7ed-3368115f7f72
  PubMed
• 49 Bertilsson L, Carrillo JA, Dahl ML. et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473
  CrossrefPubMedGoogle Scholar
• 50 Ghotbi R, Christensen M, Roh HK. et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-546
  CrossrefPubMedGoogle Scholar
• 51 Perry PJ, Bever KA, Arndt S. et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-738
  CrossrefPubMedGoogle Scholar
• 52 Haslemo T, Eikeseth PH, Tanum L. et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049-1053
  CrossrefPubMedGoogle Scholar
• 53 Dobrinas M, Cornuz J, Oneda B. et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117-125
  CrossrefPubMedGoogle Scholar
• 54 Wagner E, McMahon L, Falkai P. et al. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatr Scand 2020; 142: 456-466
  CrossrefPubMedGoogle Scholar
• 55 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
  CrossrefPubMedGoogle Scholar
• 56 Schoretsanitis G, Kane JM, Ruan CJ. et al. Comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 2019; 12: 603-621
  CrossrefPubMedGoogle Scholar
• 57 Chang WH, Lin SK, Lane HY. et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 723-739
  CrossrefPubMedGoogle Scholar
• 58 de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
  CrossrefPubMedGoogle Scholar
• 59 Loi CM, Smith DA, Dalvie D. Which metabolites circulate?. Drug Metab Dispos 2013; 41: 933-951
  CrossrefPubMedGoogle Scholar
• 60 Schaber G, Stevens I, Gaertner HJ. et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 1998; 46: 453-459
  CrossrefPubMedGoogle Scholar
• 61 Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993; 245: 179-182
  CrossrefPubMedGoogle Scholar
• 62 Ruan CJ, Zang YN, Wang CY. et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019; 39: 135-144
  CrossrefPubMedGoogle Scholar
• 63 Jerling M, Lindström L, Bondesson U. et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-374
  CrossrefPubMedGoogle Scholar
• 64 Spina E, Barbieri MA, Cicala G. et al. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel) 2020; 13: 439
  CrossrefPubMedGoogle Scholar
• 65 Ruan CJ, Zang YN, Cheng YH. et al. Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. Psychother Psychosom 2020; 89: 255-257
  CrossrefPubMedGoogle Scholar
• 66 de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55: 491-493
  CrossrefPubMedGoogle Scholar
• 67 Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
  CrossrefPubMedGoogle Scholar
• 68 Ruan CJ, Wang CY, Tang YL. et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. J Clin Psychopharmacol 2019; 39: 644-648
  CrossrefPubMedGoogle Scholar
• 69 de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit 2020; 42: 159-161
  CrossrefPubMedGoogle Scholar
• 70 Facciolà G, Avenoso A, Scordo MG. et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999; 21: 341-345
  CrossrefPubMedGoogle Scholar
• 71 Wong JO, Leung SP, Mak T. et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 251-264
  CrossrefPubMedGoogle Scholar
• 72 Diaz FJ, Santoro V, Spina E. et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91
  Article in Thieme ConnectPubMedGoogle Scholar
• 73 Rajkumar AP, Poonkuzhali B, Kuruvilla A. et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50-56
  CrossrefPubMedGoogle Scholar
• 74 Spina E, D'Arrigo C, Santoro V. et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit 2009; 31: 758-763
  CrossrefPubMedGoogle Scholar
• 75 Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol 2018; 38: 442-446
  CrossrefPubMedGoogle Scholar
• 76 Kuzin M, Haen E, Hiemke C. et al. Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. J Psychopharmacol 2021; 35: 273-278
  CrossrefPubMedGoogle Scholar
• 77 Zarezadeh M, Saedisomeolia A, Shekarabi M. et al. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. Eur J Nutr 2021; 60: 2905-2921
  CrossrefPubMedGoogle Scholar
• 78 Moschny N, Hefner G, Grohmann R. et al. Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics. Pharmaceuticals (Basel) 2021; 14: 514
  CrossrefPubMedGoogle Scholar
• 79 Clark SR, Warren NS, Kim G. et al. Elevated clozapine levels associated with infection: A systematic review. Schizophr Res 2018; 192: 50-56
  CrossrefPubMedGoogle Scholar
• 80 Nielsen R, Akey JM, Jakobsson M. et al. Tracing the peopling of the world through genomics. Nature 2017; 541: 302-310
  CrossrefPubMedGoogle Scholar
• 81 de Leon J, Rajkumar AP, Kaithi AR. et al. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian J Psychol Med 2020; 42: 4-10
  CrossrefPubMedGoogle Scholar
• 82 Suhas S, Kumar V, Damodharan D. et al. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. Schizophr Res 2020; 222: 195-201
  CrossrefPubMedGoogle Scholar
• 83 González-Esquivel DF, Jung-Cook H, Baptista T. et al. Amerindians may need clozapine dosing similar to that of Asians. Rev Psiquiatr Salud Ment. 2021 14: 177–179
  PubMedGoogle Scholar
• 84 Menkes DB, Glue P, Gale C. et al. Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine 2018; 27: 134-137
  CrossrefPubMedGoogle Scholar
• 85 Zang YN, Dong F, Li AN. et al. The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients. Eur J Drug Metab Pharmacokinet 2021; 46: 353-37
  CrossrefPubMedGoogle Scholar
• 86 Sathirakul K, Chan C, Teng L. et al. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol 2003; 56: 184-187
  CrossrefPubMedGoogle Scholar
• 87 Bigos KL, Pollock BG, Coley KC. et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157-165
  CrossrefPubMedGoogle Scholar
• 88 Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?. Pharmacogenomics 2020; 21: 369-373
  CrossrefPubMedGoogle Scholar
• 89 The Dutch Pharmacogenomic Working Group. Phamacogenomic recommendations, farmacogenetica-update. 2020 Available at www.knmp.nl/
  PubMedGoogle Scholar
• 90 Dobrinas M, Cornuz J, Eap CB. Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. Pharmacogenet Genomics 2013; 23: 286-292
  CrossrefPubMedGoogle Scholar
• 91 Jakobsen MI, Larsen JR, Svensson CK. et al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand 2017; 135: 159-169
  CrossrefPubMedGoogle Scholar
• 92 Schoretsanitis G, Smith RL, Molden E. et al. European Caucasians may need lower minimum therapeutic clozapine doses than those customarily proposed. J Clin Psychopharmacol 2021; 41: 140-147
  CrossrefPubMedGoogle Scholar
• 93 Rostami-Hodjegan A, Amin AM, Spencer EP. et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70-78
  CrossrefPubMedGoogle Scholar
• 94 Quiles C, Verdoux H. La clozapine. Encyclopédie Médico-chirurgicale. Paris: Elsevier Masson SAS; 2020
  Google Scholar
• 95 Netherlands clozapine collaboration group [Internet]. Guideline for the use of clozapine http://www.clozapinepluswerkgroep.nl/wp-content/uploads/2013/07/Guideline-for-the-use-of-Clozapine-2013.pdf
  PubMed
• 96 Taylor DM, Barnes TRE, Young AH. Maudsley Prescribing Guidelines in Psychiatry. 13th edition. Hosbroken, NJ: Wiley-Blackwell; 2018
  Google Scholar
• 97 Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329-338
  PubMedGoogle Scholar
• 98 Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746-754
  CrossrefPubMedGoogle Scholar
• 99 Citrome L. Schizophrenia life-threatening and life-saving treatment?. Curr Psychiatry 2009; 8: 57-63
  PubMedGoogle Scholar
• 100 Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6: 134-144
  CrossrefPubMedGoogle Scholar
• 101 Marder SR, Yang YS. Chapter 25. Clozapine. In: Schatzberg AF, Nemeroff CB, Ed. The American Psychiatric Association Publishing textbook of psychopharmacology. 5th edition. Washington, DC: American Psychiatric Association Publishing; 2017: 623-648
  CrossrefGoogle Scholar
• 102 Meyer JM, Stahl SM. The clozapine handbook: Stahl’s handbooks (Stahl's essential psychopharmacology handbooks). Cambridge: Cambridge University Press; 2020
  Google Scholar
• 103 de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262-273
  CrossrefPubMedGoogle Scholar
• 104 Simpson GM, Josiassen RC, Stanilla JK. et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999; 156: 1744-1750
  CrossrefPubMedGoogle Scholar
• 105 Cohen D, Bogers JP, van Dijk D. et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307-1312
  CrossrefPubMedGoogle Scholar
• 106 Siskind D, Sidhu A, Cross J. et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry 2020; 54: 467-481
  CrossrefPubMedGoogle Scholar
• 107 Wang XQ, Lv B, Wang HF. et al. Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014. J Clin Neurosci 2015; 22: 1005-1011
  CrossrefPubMedGoogle Scholar
• 108 Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015; 132: 240-241
  CrossrefPubMedGoogle Scholar
• 109 de Leon J, Tang YL, Baptista T. et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatr Scand 2015; 132: 242-243
  CrossrefPubMedGoogle Scholar
• 110 Bandelow B, Degner D, Kreusch U. et al. Myocarditis under therapy with clozapine. Schizophr Res 1995; 17: 293-294
  CrossrefPubMedGoogle Scholar
• 111 Pui-yin Chung J, Shiu-yin Chong C, Chung KF. et al. The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53: 857-862
  CrossrefPubMedGoogle Scholar
• 112 Ifteni P, Nielsen J, Burtea V. et al. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand 2014; 130: 25-29
  CrossrefPubMedGoogle Scholar
• 113 Ifteni P, Correll CU, Nielsen J. et al. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord 2014; 166: 168-172
  CrossrefPubMedGoogle Scholar
• 114 Aksoy Poyraz C, Turan Ş, Demirel ÖF. et al. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Ther Adv Psychopharmacol 2015; 5: 237-242
  CrossrefPubMedGoogle Scholar
• 115 Lochhead JD, Nelson MA, Schneider AL. Risks and benefits of rapid clozapine titration. Ment Illn 2016; 8: 6457
  PubMedGoogle Scholar
• 116 Chopra N, de Leon J. Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy. Int J Psychiatry Med 2016; 51: 104-115
  CrossrefPubMedGoogle Scholar
• 117 Poyraz CA, Özdemir A, Sağlam NG. et al. Rapid clozapine titration in patients with treatment refractory schizophrenia. Psychiatr Q 2016; 87: 315-322
  CrossrefPubMedGoogle Scholar
• 118 de Leon J, Rhee DW, Kondracke A. et al. Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York Hospital. Psychosomatics 2020; 61: 102-103
  CrossrefPubMedGoogle Scholar
• 119 Danilewitz M, Rafizadeh R, Bousman CA. Successful clozapine rechallenge after suspected clozapine-associated myocarditis: a case report. J Clin Psychopharmacol 2021; 41: 218-220
  CrossrefPubMedGoogle Scholar
• 120 Verdoux H, Quiles C, de Leon J. Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. Schizophr Res 2019; 211: 1-9
  CrossrefPubMedGoogle Scholar
• 121 Rohde C, Polcwiartek C, Kragholm K. et al. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand 2018; 137: 47-53
  CrossrefPubMedGoogle Scholar
• 122 Chopra N, Ruan CJ, McCollum B. et al. High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers. Rev Colomb Psiquiatr 2020; 49: 84-95
  CrossrefPubMedGoogle Scholar
• 123 Subramanian S, Völlm BA, Huband N. Clozapine dose for schizophrenia. Cochrane Database Syst Rev 2017; 6: CD009555
  PubMedGoogle Scholar
• 124 Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 2017; 102: 688-700
  CrossrefPubMedGoogle Scholar
• 125 Allorge D, Chevalier D, Lo-Guidice JM. et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003; 56: 341-344
  CrossrefPubMedGoogle Scholar
• 126 Ito M, Katono Y, Oda A. et al. Functional characterization of 20 allelic variants of CYP1A2. Drug Metab Pharmacokinet 2015; 30: 247-252
  CrossrefPubMedGoogle Scholar
• 127 Soyama A, Saito Y, Hanioka N. et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005; 20: 24-33
  CrossrefPubMedGoogle Scholar
• 128 Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 1998; 55: 1048-1050
  CrossrefPubMedGoogle Scholar
• 129 VanderZwaag C, McGee M, McEvoy JP. et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-1584
  CrossrefPubMedGoogle Scholar
• 130 Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42: 607-618
  CrossrefPubMedGoogle Scholar

• Supplementary Material